-
Domestic biomedical talents are popular, and the proportion of mid-to-high-end talents in the high-salary segment has increased significantly
Time of Update: 2021-11-15
Recently, an organization released the "Report on Recruitment of Talents in the Biomedical Field for the First Half of 2021" (the "Report"), showing that the proportion of high-end talents in the biomedical industry has increased significantly .
-
A large number of domestic pharmaceutical companies are accelerating innovation through the License-in model
Time of Update: 2021-11-15
A large number of pharmaceutical companies are adopting the License-in model to enrich their product pipelines and accelerate innovation .
In this context, the industry believes that the capital market will still be more inclined to pharmaceutical companies with independent innovation capabilities.
-
Recently, many large pharmaceutical companies’ new drug R&D projects have been terminated
Time of Update: 2021-11-15
In addition to Eli Lilly, there are reports that Novartis has also decided to abandon the gene therapy AVXS-201 research and development plan in the near future .
-
The third quarterly report of listed pharmaceutical equipment companies is released: new opportunities in the industry appear
Time of Update: 2021-11-15
Recently, three quarterly reports of listed companies in the pharmaceutical equipment industry, including Chutian Technology, Tofflon, Xinlai Yingcai, and Canaan Technology, have been released intensively .
-
839 pharmacies Dashenlin accepted
Time of Update: 2021-11-15
In the first three quarters of this year, Dashenlin had 29 investment mergers and acquisitions, involving a total of 839 stores .
15 percentage points from the previous year; Chinese ginseng medicinal materials this year The performance of the first three quarters was also good, with total revenue of 1.
-
116 pharmaceutical companies released three quarterly reports, and the performance of these companies has declined
Time of Update: 2021-11-15
Among them, Tai Chi Group is one of the pharmaceutical companies with a relatively large increase in revenue and net profit in the three quarterly reports that have been published .
70% year-on-year; net profit attributable to shareholders of listed companies was 248 million yuan, an increase of 1425.
-
Ministry of Commerce: Cultivate 5-10 50 billion pharmacies within 5 years
Time of Update: 2021-11-15
Accelerate the establishment of a modern pharmaceutical logistics service system with reasonable layout, advanced technology, convenient and efficient, green and environmentally friendly, safe and orderly, and improve the service functions of the national pharmaceutical logistics network composed of regional logistics centers, provincial logistics centers, and county distribution centers, and develop Multi-level pharmaceutical supply chain logistics network .
-
Following Ganli Pharmaceutical, United Laboratories, and Tonghua Dongbao, another insulin glargine was approved for listing
Time of Update: 2021-11-15
On October 26, 2021, Yichang Dongyangguang announced that insulin glargine was officially approved for listing, becoming the fourth domestic company to obtain the registration approval for this product after Ganli Pharmaceutical, United Laboratories, and Tonghua Dongbao .
-
The National Health Commission publicly solicits opinions on the Internet diagnosis and treatment regulations (draft for comments)
Time of Update: 2021-11-15
Article 10: Local health authorities at all levels shall publish to the public the list of medical institutions approved to conduct Internet diagnosis and treatment in their jurisdiction, supervision telephone numbers and other supervision methods on the provincial supervision platform, set up complaint acceptance channels, and deal with violations of laws and regulations in a timely manner .
-
Harbin Sanlian Ondansetron Hydrochloride Injection Passed the Consistency Evaluation of Generic Drugs
Time of Update: 2021-11-15
On October 31, Harbin Sanlian issued an announcement stating that the company has recently received a supplementary drug application approval notice issued by the National Medical Products Administrat
-
Comprehensive inventory: policies related to the life cycle management of anti-tumor drugs
Time of Update: 2021-11-15
This article counts the policies and regulations related to the research and development of anti-tumor drugs in recent years for everyone to take a look at .
-
The reshuffle of the pharmaceutical manufacturing industry is imminent, and the transformation of intelligent manufacturing is the key
Time of Update: 2021-11-15
For another example, in Jiuzhitang's smart factory for solid preparations of traditional Chinese medicine, the application of the new model has significantly changed the company's previous experience of relying on people in pharmaceuticals, greatly improving work efficiency, and product quality more stable .
-
Under the trend of innovation, the pharmaceutical industry has set off a wave of cooperation
Time of Update: 2021-11-15
On October 22, Genetron Health, which focuses on providing tumor molecular detection, cancer early screening and companion diagnostic development services, announced that it has entered into an agreement with Jiangsu Fosun Pharmaceutical Sales Co.
-
Mid-term clinical failure GSK stops developing anti-GM-CSF monoclonal antibody otilimab to treat COVID-19
Time of Update: 2021-11-15
The data shows that in patients of all ages, compared with standard care (including antiviral therapy and glucocorticoids), a single dose of otilimab + standard care treatment for 28 days failed to improve the survival of patients with severe COVID-19-related lung diseases.
-
A new drug research and development boom in China, and a variety of blockbuster drugs will be launched soon
Time of Update: 2021-11-15
In addition, on October 22, Sihuan Pharmaceutical also issued an announcement stating that the China National Medical Products Administration has accepted the New Drug Application (NDA) for Anaprazole Sodium Enteric-Coated Tablets .
-
my country's first "Report on the Development of Rheumatoid Arthritis in China" was officially published
Time of Update: 2021-11-15
" Director of the National Clinical Research Center for Skin and Immune Diseases, Executive Director of the Chinese Medical Doctor Association and President of Rheumatology and Immunology Branch, Beijing Professor Zeng Xiaofeng, Director of the Department of Rheumatology and Immunology of Xiehe Hospital, pointed out that “The Annual Report of RA” is based on patient diagnosis and treatment data from tertiary hospitals to primary medical institutions.
-
The three pharmaceutical equipment industry standards will be implemented on February 1 next year!
Time of Update: 2021-11-15
According to the list of 250 industry standard numbers, names, and main contents in Annex 1, the machinery industry includes three pharmaceutical equipment industry standards, including automatic Chinese medicine decoction systems, filter integrity testers, and vaporized hydrogen peroxide concentration detectors, all of which follow It will be implemented on February 1, 2022 .
-
It is getting easier to open a pharmacy, which is leading to intensified market competition
Time of Update: 2021-11-15
It is understood that in order to deepen the reform of decentralization , regulation and service, and to further reduce the time limit for the establishment of pharmaceutical companies, Zhejiang Province had cancelled the approval for the establishment of retail pharmacies as early as last year .
-
The large-scale price increase of Chinese medicinal materials in this area has made it an industry consensus to improve forecasting and control capabilities
Time of Update: 2021-11-15
Under the background that the price increase of Chinese medicinal materials will be a long-term trend, the industry generally believes that Chinese medicine companies need to strengthen the monitoring of market prices to improve their control and forecasting capabilities of market conditions .
-
The domestic medical device industry continues to develop well, and machinery companies need to break through the homogeneous competition
Time of Update: 2021-11-15
In recent years, the development of China's medical device industry has clearly entered the fast lane, and the performance of many machinery companies is also developing continuously .
In addition to Mindray Medical, on October 15th, A-share listed company Ingram Medical also issued a three-quarter report performance forecast.
